Lyra Therapeutics Stock Z Score
| LYRA Stock | USD 0.18 0.02 10.00% |
Lyra | Z Score |
Lyra Therapeutics Company Z Score Analysis
Lyra Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Lyra Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Lyra Therapeutics is extremely important. It helps to project a fair market value of Lyra Stock properly, considering its historical fundamentals such as Z Score. Since Lyra Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lyra Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lyra Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Lyra Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Lyra Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Lyra Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lyra Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lyra Therapeutics' value.| Shares | Everhart Financial Group, Inc. | 2024-09-30 | 252.7 K | Boothbay Fund Management, Llc | 2024-06-30 | 232.7 K | Northern Trust Corp | 2024-09-30 | 183.3 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 159.2 K | New York State Common Retirement Fund | 2024-09-30 | 154.8 K | Simplex Trading, Llc | 2024-06-30 | 129.1 K | Clearline Capital Lp | 2024-06-30 | 119.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 111.6 K | Bank Of America Corp | 2024-06-30 | 86.5 K | Perceptive Advisors Llc | 2024-09-30 | 12.8 M | Citadel Advisors Llc | 2024-06-30 | 4.8 M |
Lyra Fundamentals
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (49.43) % | ||||
| Current Valuation | (4.4 M) | ||||
| Shares Outstanding | 65.46 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 58.82 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Book | 0.58 X | ||||
| Price To Sales | 8.09 X | ||||
| Revenue | 1.56 M | ||||
| Gross Profit | (34.23 M) | ||||
| EBITDA | (65.25 M) | ||||
| Net Income | (62.68 M) | ||||
| Cash And Equivalents | 120.67 M | ||||
| Cash Per Share | 3.79 X | ||||
| Total Debt | 26.88 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (63.3 M) | ||||
| Short Ratio | 1.54 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Price To Earnings To Growth | 1.61 X | ||||
| Target Price | 1.25 | ||||
| Number Of Employees | 88 | ||||
| Beta | -0.036 | ||||
| Market Capitalization | 11.91 M | ||||
| Total Asset | 142.6 M | ||||
| Retained Earnings | (311.36 M) | ||||
| Working Capital | 85.22 M | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 4.82 M | ||||
| Net Asset | 142.6 M |
About Lyra Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lyra Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:Check out Lyra Therapeutics Piotroski F Score and Lyra Therapeutics Valuation analysis. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.64) | Return On Assets (0.42) | Return On Equity (1.86) |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.